SCHEMBL2006373

SCHEMBL2006373

COc1cc2c(CC(=O)O)c(C)n(Cc3ccc(Cl)cc3)c2cc1F

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.69
CYP1A2 P05177 3/20 0.69
CYP2C9 P11712 3/20 0.69
PMP22 Q01453 3/20 0.69
CYP3A4 P08684 2/20 0.69
TSHR P16473 2/20 0.69
CYP2C19 P33261 2/20 0.69
MEN1 O00255 2/20 0.69
MAPT P10636 2/20 0.69
KMT2A Q03164 2/20 0.69
HIF1A Q16665 2/20 0.69
RGS12 O14924 1/20 0.69
ALDH1A1 P00352 1/20 0.69
PKM P14618 1/20 0.69
NFKB1 P19838 1/20 0.69
MAPK1 P28482 1/20 0.69
GNAI1 P63096 1/20 0.69
KDM4E B2RXH2 2/20 0.61
NPSR1 Q6W5P4 2/20 0.61
BLM P54132 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5444339 0.93 LMNA (0.62) LMNACYP1A2CYP2C9PMP22CYP3A4
SCHEMBL5438274 0.93 LMNA (0.72) LMNACYP1A2CYP2C9PMP22CYP3A4
SCHEMBL5447472 0.92 LMNA (0.61) LMNACYP1A2CYP2C9PMP22CYP3A4
SCHEMBL5442512 0.92 LMNA (0.70) LMNACYP1A2CYP2C9PMP22CYP3A4
SCHEMBL5435351 0.91 PLA2G2A (0.67) LMNACYP1A2CYP2C9PMP22CYP3A4
SCHEMBL5444654 0.91 PTGS2 (0.69) LMNACYP1A2CYP2C9PMP22CYP3A4
SCHEMBL2003800 0.89 LMNA (0.71) LMNACYP1A2CYP2C9PMP22CYP3A4
SCHEMBL5444279 0.89 LMNA (0.58) LMNACYP1A2CYP2C9PMP22CYP3A4
SCHEMBL5442466 0.89 LMNA (0.58) LMNACYP1A2CYP2C9PMP22CYP3A4
SCHEMBL5446051 0.88 LMNA (0.57) LMNACYP1A2CYP2C9PMP22CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960544-B2 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
US-20070161698-A1 Modulators of CRTH2 Activity MICROBIA, INC. 2007-07-12 US disclosed
US-7205329-B2 Modulators of CRTH2 activity MICROBIA, INC. (US) 2007-04-17 US disclosed
US-20060135591-A1 Modulators of CRTH2 activity IRONWOOD PHARMACEUTICALS, INC. 2006-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135591-A1 Modulators of CRTH2 activity HRH2, HRH1, MRGPRX2 LMNA 4458/4885CYP1A2 2697/4885CYP2C9 4746/4885
US-20070161698-A1 Modulators of CRTH2 Activity HRH2, HRH1, MRGPRX2 LMNA 4458/4885CYP1A2 2697/4885CYP2C9 4746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.